| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | JUNO THERAPEUTICS INCORPORATED | 1,229,512 | 54,062,000 | 30.09% | ||
| 2 | PARATEK PHARMACEUTICALS INC | 2,138,872 | 40,574,000 | 22.58% | ||
| 3 | Egalet Corp | 2,814,928 | 31,021,000 | 17.26% | ||
| 4 | FIBROGEN INC COM | 822,175 | 25,052,000 | 13.94% | ||
| 5 | Nabriva Therapeutics AG | 1,145,890 | 11,023,000 | 6.13% | ||
| 6 | Pieris Pharmaceuticals | 2,483,949 | 5,688,000 | 3.17% | ||
| 7 | ESSA Pharma | 1,090,909 | 4,636,000 | 2.58% | ||
| 8 | Proteon Therapeutics | 250,000 | 3,878,000 | 2.16% | ||
| 9 | Dicerna Pharmaceuticals | 223,457 | 2,652,000 | 1.48% | ||
| 10 | CymaBay Therapeutics | 650,000 | 1,099,000 | 0.61% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-16-013919, filed 2016.02.10).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
